Leap Therapeutics, Inc. (LPTX)

$1.17

+0.02 (+1.74%)
Rating:
Recommendation:
Buy
Symbol LPTX
Price $1.17
Beta 0.734
Volume Avg. 0.80M
Market Cap 103.333M
Shares () -
52 Week Range 0.92-4.17
1y Target Est -
DCF Unlevered LPTX DCF ->
DCF Levered LPTX LDCF ->
ROE -47.38% Strong Sell
ROA -39.50% Strong Sell
Operating Margin -
Debt / Equity 7.45% Neutral
P/E -
P/B 1.34 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest LPTX news


Dr. Christopher Mirabelli
Healthcare
Biotechnology
NASDAQ Global Market

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.